CD274 and neoplasm: The combined use of anti-PD-1 and anti-PD-L1 antibodies to block the PD-1/PD-L1 pathway specifically can hinder tumor stem cell proliferation and decrease tumor recurrence rates, showing promise for gastric cancer treatment.